Medical Device Registration Consulting In China
China medical device registration consulting should settle the regulatory route before a manufacturer commissions China-specific testing or translates a full dossier. The decisions depend on the device’s intended purpose, risk classification, manufacturing location, evidence and applicant—not simply its EU or US status.
Select the route: classification × manufacturing origin
Under SAMR Decree No. 47, Class I uses filing, whereas Classes II and III use registration. The authority also changes with domestic versus imported origin. The table is a starting framework, not a classification decision for a specific product.
| Product and origin | Regulatory path | What to confirm first |
|---|---|---|
| Domestic Class I | Filing with the drug regulator of a city divided into districts. | Confirm the legal manufacturer and a defensible Class I classification. |
| Imported Class I | Filing with NMPA. | Confirm that the product is imported and the overseas filing entity and China agent are identified. |
| Domestic Class II | Registration with the provincial-level drug regulator. | Confirm classification and the domestic registrant/manufacturing arrangement. |
| Domestic Class III | Registration with NMPA. | Confirm high-risk features, intended purpose and applicable technical guidance. |
| Imported Class II or III | Registration with NMPA. | Confirm import status, authorized China agent, clinical path and dossier ownership. |
Four facts that can change the answer
Start with China’s classification rules and catalogue, not an overseas certificate. Where no suitable catalogue entry exists, a classification determination may be needed; Decree No. 47 also addresses a direct Class III application for a new device outside the catalogue. Test these product facts together:
- Exact intended medical purpose, indications, claims, target users and use environment; promotional language can change the scope to be assessed.
- Whether the device is invasive, implanted, active, in contact with patients, or used for critical decisions; duration and risk matter.
- Software functions, algorithms, accessories and kits; an apparently similar product need not have the same China classification.
- Model families, variations, manufacturing site and domestic/imported status; these can change grouping, evidence and the competent authority.
Evidence-reuse gap matrix: do not equate existing reports with acceptance
A consultant should map each existing document against China’s actual intended use, product technical requirements and applicable mandatory standards. “Available” and “usable” are different conclusions.
| Existing input | China-specific gap question | Decision before spending |
|---|---|---|
| EU/FDA dossier, risk file, test reports | Do the tested configurations and methods support Chinese product technical requirements and mandatory standards? | Reuse with a justified bridge, update studies, or commission targeted tests; do not assume every overseas report is accepted. |
| Clinical literature, equivalence and trials | Is a clinical-evaluation exemption applicable, or do existing data support the device’s China indications and differences? | Document the exemption/evaluation rationale; plan a China-compliant study only if the evidence is insufficient. |
| Marketing authorisation and manufacturer records | Are the import marketing documents, actual applicant, sites and product identity aligned? Does a statutory exception apply? | Verify the correct evidence before translation and submission. |
| Chinese materials, agent and change history | Can Chinese submissions be traced to originals, and have labels, software or manufacturing changes affected scope? | Assign document owners and resolve inconsistencies before the filing route is locked. |
A four-gate decision sequence before filing
Use these gates as a strategic stop/go tool, not as a detailed application checklist:
- Gate 1 — Freeze the device definition: intended use, variants, mechanism, risk, accessories, manufacturing sites and existing approvals.
- Gate 2 — Issue a reasoned China classification and origin memo, identify the authority, and record uncertainty requiring confirmation.
- Gate 3 — Compare the China requirements with test, clinical, quality, labelling and import evidence; assign each gap an owner and a resolution route.
- Gate 4 — Choose sequencing: clarification first if classification is uncertain; otherwise close decisive gaps, appoint the necessary parties and then begin execution.
Foreign applicants, exceptions and change control
An overseas registration or filing applicant must appoint a legal-person enterprise in China as its agent. The applicant remains responsible for the authenticity of submissions and lifecycle quality. Submission documents must be in Chinese, with originals where translated. For imports, evidence of marketing in the relevant country or region is normally required, subject to the precise alternatives and the innovative-device exception in Article 18; a CE mark alone is not a China authorisation.
Do not treat clinical trials, China-based laboratory testing or a change of applicant as automatic. Decree No. 47 permits applicant self-testing or testing by a qualified entrusted institution and differentiates clinical-evaluation exemption, literature/equivalence and trials. A China manufacturing plan can engage the separate NMPA 2025 notice on manufacture of already registered imported devices; eligibility and dossier reuse require case review. For projects extending beyond 1 November 2026, assess the revised medical-device GMP scheduled to take effect on that date.
Where strategic advice stops and execution starts
The deliverable from an advisory review is a written classification rationale, a route decision, a priority-ranked gap matrix and a recommended next action. Detailed submission operations, representation and non-device certification are separate workstreams:
Official regulatory references
Check the Chinese-language original and current NMPA notices when a product-specific decision is made; English translations are reference material.
Questions that affect the decision
Can a CE mark or FDA clearance replace NMPA registration?
No. It can be useful source evidence, but China’s classification, filing/registration route, product technical requirements and clinical justification must be assessed independently.
Does Class I mean there is nothing to file or test?
No. Class I follows a filing route rather than Class II/III registration. Applicable technical requirements and supporting evidence still matter; do not confuse the absence of a registration review with an absence of obligations.
Is a clinical trial always required for Class II or III?
No. Check whether clinical evaluation is exempt; otherwise assess literature and comparable-device clinical data before deciding whether a trial is necessary. This is specific to the product and its indications.
Can our Chinese distributor automatically act as agent?
Not automatically. An overseas applicant must designate an eligible legal-person enterprise in China as agent, and the appointment and ongoing responsibilities should be checked separately from commercial distribution.
Can an imported approval simply be transferred to a new Chinese factory?
Do not assume so. Domestic manufacture has its own registration/applicant implications. Review the actual controller, sites and applicability of the 2025 NMPA notice before reusing an import dossier.